HHS INSPECTOR GENERAL’s WORK PLAN FOR FISCAL 1991 INCLUDES REVIEW OF DIRECT-TO-CONSUMER ADVERTISING AND FDA’s ORPHAN DRUG APPROVAL PROCEDURES
The HHS Office of the Inspector General plans to conduct a review of direct-to-consumer prescription drug advertising in early 1991, according to a draft work plan for fiscal years 1990 and 1991. The study "will analyze the range and nature of prescription drug advertising; its effect on decisions made by consumers to visit physicians and request or demand advertised treatments or drugs; and its effect on drug pricing," the document states. The review will be conducted by the IG's Office of Analysis and Inspections, the IG arm responsible for analyzing HHS programs and policies. Although the IG work plan is a draft that is subject to extensive revision as the year progresses and new priorities emerge, the planned investigations reflect the IG's current interests and areas that may become hot issues in HHS and Congress, if they're not already. Another topical area of investigation slated for review by the IG next year is the Orphan Drug Act. The IG's Audit Office, which provides policy direction for HHS programs and operations as well as conducting comprehensive audits, is expected to begin its review of FDA Orphan Drug Act approval procedures in the third quarter of 1991 (fourth quarter of the government's fiscal year). The purpose of the review, according to the draft work plan, "is to determine whether necessary clinical and nonclinical investigations have been conducted prior to approving a product as an orphan drug." Other planned IG projects include a review of the adequacy of funding for AZT, scheduled for the fourth quarter of fiscal 1990; a review of utilization and pricing issues raised by Medicare use of erythropoietin, scheduled for the fourth quarter of fiscal 1990; and a review of prescription drug reimbursement programs to see if the government is taking advantage of available savings, which is planned for the fourth quarter of fiscal 1991.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth